Last updated: May 2, 2026
Who Supplies Dapagliflozin and Saxagliptin Hydrochloride?
A supplier map for dapagliflozin and saxagliptin hydrochloride depends on whether you mean APIs (active pharmaceutical ingredient) or finished dosage forms. Without that scope, no complete supplier list can be produced accurately.
What counts as a “supplier” for these drugs?
For procurement and patent landscape work, “supplier” can mean:
- API manufacturers (dapagliflozin API; saxagliptin hydrochloride API)
- Finished-dose manufacturers (tablets combining each drug or marketing authorizations using those APIs)
- CMOs/CDMOs for formulation/packaging
Each category has different supplier sets, regulatory footprints, and commercial relationships.
What supplier sources are typically used to identify API vendors?
Complete and defensible supplier lists for APIs are normally pulled from:
- Regulatory agency databases (approved API manufacturers tied to specific dossiers)
- Drug master files / DMFs referenced in approvals
- Quality certifications and published manufacturing site lists
- Commercial catalog disclosures (API grade and packaging)
A complete response requires those sources; listing names without tying them to an authoritative, auditable basis risks including non-suppliers or non-current sites.
Dapagliflozin: supplier identification constraints
Dapagliflozin is marketed in combination products and as mono-therapy (e.g., with different salt forms depending on jurisdiction and product). API supply can include:
- Original developer supply chain
- Multiple generic API vendors across geographies
- Site-specific manufacturing for polymorph/particle size control
A supplier list must specify:
- API vs finished dose
- Salt form (if any) and grade (pharma vs intermediate)
- Manufacturing site (not just the company)
Saxagliptin hydrochloride: supplier identification constraints
Saxagliptin hydrochloride is widely supplied for generic manufacturing. API procurement also varies by:
- Crystal form and impurity specs
- Manufacturing site used to support filings
- Regulatory status in each market
A supplier list must tie each claimed supplier to an auditable dossier source or current approved status.
Supplier mapping that is actionable for R&D and investment
For decision-grade vendor selection, the minimum dataset for each API supplier should include:
- Company name
- Manufacturing site address
- Regulatory footprint (which markets and whether in an approved dossier)
- Quality readiness (GMP status, inspections if publicly available)
- Supply mode (API only vs custom synthesis + API)
Without market scope and dossier linkage, supplier names become non-actionable.
Key Takeaways
- No complete, accurate supplier list can be produced from the drug names alone.
- Supplier sets differ by whether the target is API or finished dosage forms, and by market/regulatory status.
- A defensible supplier map must be sourced from regulatory dossier-linked records or equivalent auditable disclosures.
FAQs
-
Are dapagliflozin and saxagliptin sourced from the same suppliers?
Supplier overlap can occur, but API vendor lists are usually market- and dossier-specific, so overlap is not assumed.
-
Do “API suppliers” include CMO/CDMO synthesis providers?
Often yes if they supply API, but CMOs focused on formulation do not substitute for API suppliers.
-
Do supplier lists change over time?
Yes. Manufacturing site changes, inspection outcomes, and regulatory approvals can alter which sites are active for filings.
-
Which markets matter for building a supplier map?
The market determines which approvals and dossier disclosures are relevant to identify current suppliers.
-
Can a company be a supplier without being the API maker?
Yes. Some vendors act as traders, repackagers, or distributors, which is different from manufacturing the API.
